Insmed Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.

The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

Country	United States
Founded	1988
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	912
CEO	William Lewis

Contact Details

Address: 700 US Highway 202/206 Bridgewater, Virginia 08807 United States
Phone	908 977 9900
Website	insmed.com

Stock Details

Ticker Symbol	0JAV
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US4576693075
SIC Code	2836

Key Executives

Name	Position
William H. Lewis J.D., M.B.A.	President, Chief Executive Officer and Chairman
Sara M. Bonstein M.B.A.	Chief Financial Officer
Roger Adsett M.B.A.	Chief Operating Officer
John Drayton Wise M.B.A.	Chief Commercial Officer
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer
Brian K. Kaspar Ph.D.	Chief Scientific Officer
Eleanor Barisser	Associate Director of Investor Relations
Michael Alexander Smith J.D.	Chief Legal Officer and Corporate Secretary
Mandy Fahey	Executive Director of Corporate Communications
S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer